🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05336851
Recruiting Observational

Emergency PWAS in Respiratory Infectious Disease

NCT05336851 · tracked via the Priya Life Science China tracker
Sponsor
The University of Hong Kong
Phase
Observational
Started
2023-04-11
Last updated
2026-05-12

Condition(s) studied

Viral InfectionsBacterial InfectionsFungal InfectionsMixed InfectionMycobacterium InfectionInfection of Uncertain AetiologyPneumoniaSepsis

Investigational drug(s) / intervention(s)

Biomarker blood draw and saliva collection

Biomarker blood draw and saliva collection: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)

Study summary

Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).

Phase 1

1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2
2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: Patients eligible for enrolment include: With reference to previous inclusion criteria are: * Adults ≥18 years of age; AND * Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\*; AND * Informed consent. Note: scaRID is defined according to ALL three criteria: 1. Community acquired (not hospitalised for \<28 days); AND 2. Acute infection (defined as symptom onset \<8 days and any ONE of reported fever or chills or aural temperature \>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND 3. Probable respiratory infection - According to any ONE of: 1. new cough or new sputum production or 2. chest pain or 3. dyspnoea or 4. tachypnoea or 5. abnormal lung examination or 6. respiratory failure; or 7. physician's judgment (presenting with systemic or gastrointestinal symptoms). Control subjects will be drawn from two groups: * The worried well - adult patients with a National Early Warning Score (NEWS) \<3 and a temperature \<37.5°C. * Relatives or accompanying friends with no acute illness. Exclusion Criteria: * Refusal of consent; * Recent hospitalisation (\<28 days); * Enrolled in another clinical trial * Cellulitis; * Skin or orthopaedic infections; * Urinary tract infection; * Acute abdominal sepsis; * Sexual transmitted disease; * Human immunodeficiency virus (HIV) infection; * Immunocompromised/potential neutropenic fever; * Solid organ or haematopoietic stem-cell transplant within the previous 90 days; * Active graft-versus-host disease or bronchiolitis obliterans; * Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases; * Stroke; * Toxidrome; * Non-organic acute psychosis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hong Kong University Hong Kong China Recruiting

More The University of Hong Kong trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05336851 on ClinicalTrials.gov ↗ ← All trials in China